Tweets
Can I use BASDAI to asses disease in #pregnant AS patients?
Abstract #0374 #ACR22 @RheumNow; 50 women
🫃Back pain and fatigue beyond 4.5 months = not reliable
🫃BASDAI in 3rd trimester = not reliable
🫃Morning stiffness remains reliable marker of disease in pregnancy
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Abs 0478 at #ACR22 study indicates that a single screening US of temporal and axillary arteries accurately identified 83.3% of patients with subclinical GCA in an inception PMR cohort. It may not change tx but possibly timeline for tx, IMO. @RheumNow https://t.co/bEBVfxDNir https://t.co/UQ1EdniGk5
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Wanna know more about SpA in female patients? Just ask @Sineadm15! Check out my interview with her at #ACR22 @RheumNow https://t.co/NSM4pJeb6g
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
👁 What causes worse outcomes in our SpA uveitis pts? 👁
🚬 smoking Hx
🦴 ax + peripheral disease
✏️ BASDAI >4
👩🔬 HLA B27 +ve
🙋♀️ females
🧪CRP ⬆️
👁 bilat eye involvement
Abst#0373
#ACR22 @RheumNow
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO
• Rapid improvement 47.7 vs 21.4%
• TNF naive 46.6 vs 22.9%
• TNFIR 60 vs 11.8%
• Wk 24 >50% ASDAS <2.1
• Improved MRI
• Serious TEAE 0.4%
Deodhar Abs0544 https://t.co/q9dbQP5oLD #ACR22 @RheumNow https://t.co/VCJgo56JrA
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
QD Clinic - How to Treat Erosive OA (abstract #L05)
61yoWM with bilateral pain/swelling in DIPs. Labs normal, seronegative and Xrays shows evidence of DIP erosive OA.
But what works in EOA? #ACR22
https://t.co/tbIoTg6kxA https://t.co/YcW7TON0En
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Adding MTX to Pegloticase for 52 wks in gout
◦ Improved response rate by 30%
◦ Reduced discontinuation rate by 40%
◦ Greater resolution of tophi by 20%
◦ Similar safety profile in MTX vs non-MTX groups
Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
Abs 0412 by @Spondy_MD et al at #ACR22: BKZ tx showed meaningful improvements in physical function and HRQoL in nr-axSpA and AS pts with consistent responses. @RheumNow https://t.co/diGqpQKfpS https://t.co/1pdGi47IJM
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Can we use sputum to identify progression to RA in at-risk individuals?
Sputum anti-CCP-IgA anti-CCP-IgG & RF-IgM positivity = 4-fold increase risk of classified RA in IgG CCP+ at-risk individuals.
Sens 67% Spe 80%
https://t.co/o6PCvxgYGM
Abs #0533 #ACR22 #ACRBest @Rheumnow https://t.co/CxDjanjBKT
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
What’s new to treat PsA? Let’s discuss anti-IL-17A, Izokibep #ACR22 @RheumNow
Abstract #0199
💪 Izokibep 40 v. 80 mg q2 weeks SQ v. placebo
💪 135 patients, 28 sites
💪 At 12 weeks, all patient reported outcomes and PsAID subdomains significantly improved (dose dependent)
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Another study showing treatment withdrawal does not work.
Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares.
Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
